1
|
Bourkadi D, Zaoui M, Sahraoui K, Henni M, Simerabet A, Bennani M. Les tumeurs pulmonaires primitives rares : à propos de 21 cas. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
2
|
Lanez T, Henni M. Antioxidant activity and superoxide anion radical interaction with 2-(ferrocenylmethylamino) benzonitrile and 3-(ferrocenylmethylamino) benzonitrile. J IRAN CHEM SOC 2016. [DOI: 10.1007/s13738-016-0891-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
3
|
Lanez T, Henni M. Determination of binding parameters of 2-(Ferrocenylmethylamino) Benzonitrile and 3-(Ferrocenylmethylamino)Benzonitrile WITH 1,1-Diphenyl-2-Picrylhydrazyl free radical. J Fundam and Appl Sci 2016. [DOI: 10.4314/jfas.v8i1.10] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
4
|
Henni M, Fabre E, Abane R, Housset M. [New techniques in thoracic radiation therapy]. Rev Pneumol Clin 2014; 70:63-68. [PMID: 24566032 DOI: 10.1016/j.pneumo.2013.10.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/17/2013] [Revised: 10/10/2013] [Accepted: 10/25/2013] [Indexed: 06/03/2023]
Abstract
Advanced technologies have led to an improvement of target volume delineation and a higher accuracy in dose delivery. Stereotactic body radiotherapy, intensity-modulated radiotherapy and respiratory gating allow new therapeutic perspectives along with an improvement of the therapeutic ratio. Ongoing trials aim to show the magnitude of gains in patient care with technical improvements.
Collapse
Affiliation(s)
- M Henni
- Service d'oncologie radiothérapie, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France.
| | - E Fabre
- Service d'oncologie médicale, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France
| | - R Abane
- Unité CNRS UMR 7216, université Paris Diderot, 35, rue Hélène-Brion, 75013 Paris, France
| | - M Housset
- Service d'oncologie radiothérapie, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France
| |
Collapse
|
5
|
Pecuchet N, Bigot F, Henni M, Fabre E. [Therapeutic impact of molecular diagnosis in metastatic non-small cell lung cancer: targeted therapies in 2013]. Rev Pneumol Clin 2014; 70:38-46. [PMID: 24566025 DOI: 10.1016/j.pneumo.2013.12.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/03/2013] [Revised: 12/16/2013] [Accepted: 12/16/2013] [Indexed: 06/03/2023]
Abstract
Recent advances in the molecular characterization of metastatic unresectable lung cancers have markedly improved the management of patients. Today, molecular tests should be performed routinely in all patients with non-squamous non-small cell lung cancer, and in case of squamous cell carcinoma occurring in a non-smoker. In the presence of EGFR mutation or ALK rearrangement, specific inhibitors have shown superior efficacy to chemotherapy in first-line treatment for anti-EGFR (erlotinib and gefitinib) and in second-line treatment for anti-ALK (crizotinib). We will report the most recent clinical trials that aimed to identify effective therapeutic alternatives in case of acquired resistance to first-generation inhibitors (erlotinib, gefitnib, crizotinib), which inevitably occur in a median of 11-13 months at the first line setting and 7 months at the second line setting. Finally, we will describe more recently known molecular alterations such as ROS1 or RET rearrangements and HER2, BRAF, PIK3CA, DDR2 mutations. Some of these alterations are already elegible for dedicated targeted therapies within clinical trials or temporary use authorization (ATU).
Collapse
Affiliation(s)
- N Pecuchet
- Service d'oncologie médicale, hôpital européen Georges-Pompidou, 20-30, rue Leblanc, 75908 Paris cedex 15, France; Unité Inserm U775 : bases moléculaires de la réponse aux xénobiotiques, centre universitaire des Saints-Pères, 45, rue des Saints-Pères, 75006 Paris, France
| | - F Bigot
- Service d'oncologie médicale, hôpital européen Georges-Pompidou, 20-30, rue Leblanc, 75908 Paris cedex 15, France
| | - M Henni
- Service d'oncologie médicale, hôpital européen Georges-Pompidou, 20-30, rue Leblanc, 75908 Paris cedex 15, France
| | - E Fabre
- Service d'oncologie médicale, hôpital européen Georges-Pompidou, 20-30, rue Leblanc, 75908 Paris cedex 15, France; Unité Inserm U775 : bases moléculaires de la réponse aux xénobiotiques, centre universitaire des Saints-Pères, 45, rue des Saints-Pères, 75006 Paris, France.
| |
Collapse
|
6
|
Le Fur E, Chatellier G, Berger A, Emile JF, Dousset B, Nordlinger B, Berges O, Deberne M, Dessard-Diana B, Henni M, Giraud P, Housset M, Durdux C. [Tolerance and efficacy of preoperative radiation therapy for elderly patients treated for rectal cancer]. Cancer Radiother 2013; 17:202-7. [PMID: 23643361 DOI: 10.1016/j.canrad.2013.01.013] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2012] [Revised: 12/22/2012] [Accepted: 01/31/2013] [Indexed: 01/09/2023]
Abstract
PURPOSE To retrospectively assess the impact of age on tolerance and oncologic outcomes treated by neoadjuvant treatment for patients of 70 years old or above with locally advanced rectal cancer. PATIENTS AND METHODS Ninety-one consecutive patients were divided into three groups: group 1 from 70 to 75 years (n=31); group 2: 76 to 79 years (n=31) and group 3, patients aged 80 years or above (n=29). Radiation therapy was delivered according two schemes: 25Gy in five fractions (short scheme) or 45 to 50Gy with a classical fractionation (long scheme). Long scheme patients received a concomitant chemotherapy with 5-fluoro-uracile alone or associated with oxaliplatin. RESULTS The three groups were comparable for performance status, Charlson's score and T staging. Long scheme radiation therapy and chemotherapy were performed in 77.5, 74.5 and 48.3% of patients (P=0.03) and 77.4, 71 and 41.4% (P=0.006) in the groups 1, 2 and 3, respectively. All patients treated with the short scheme irradiation received the treatment without any acute toxicity. In the long scheme group, 65% of patients received the treatment on time and grade 3 or above toxicity was observed in 12% of patients who did not receive oxaliplatin and in 48% of patients who received oxaliplatin. The overall survival rate at 3 and 5 years was 66.9% and 60.8% in the group 1, 90.5% and 75.9% in the group 2 and 80.5% and 73.8% in the group 3 (P=0.15). CONCLUSION Neoadjuvant treatment is feasible with encouraging survival rates for patients aged 70 years and older. Short scheme radiation therapy seems to be an interesting option in this population.
Collapse
Affiliation(s)
- E Le Fur
- Service de radiothérapie, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Kreps S, Tamby E, Dessard Diana B, Berges O, Botti M, Deberne M, Henni M, Durdux C, Housset M, Giraud P. Comparaison de la toxicité muqueuse et cutanée de la RCMI et de la radiothérapie classique associée au cetuximab. Cancer Radiother 2011. [DOI: 10.1016/j.canrad.2011.07.067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
8
|
Yassa M, Saliou M, De Rycke Y, Hemery C, Henni M, Bachaud J, Thiounn N, Cosset J, Giraud P. Male pattern baldness and the risk of prostate cancer. Ann Oncol 2011; 22:1824-7. [DOI: 10.1093/annonc/mdq695] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
9
|
Gligorov J, Bastit L, Gervais H, Henni M, Kahila W, Lepillé D, Luporsi E, Sasso G, Attali P, Azria D. Prevalence and Treatment of Oropharyngeal Candidiasis in Cancer Patients: The CANDIDOSCOPE Study. Int J Radiat Oncol Biol Phys 2009. [DOI: 10.1016/j.ijrobp.2009.07.311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
10
|
Boukhelif W, Henni M, Abrous-Anane S, Maisonobe JA, Klotz S, Leignel D, Dessard-Diana B, Giraud P, Durdux C, Housset M. Comparaison de deux techniques d’irradiation sus-claviculaire dans le cancer du sein. Cancer Radiother 2009. [DOI: 10.1016/j.canrad.2009.08.132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
11
|
Fernandez D, Maisonobe JA, Leignel D, Durdux C, Henni M, Dessard-Diana B, Housset M, Giraud P. Prise en compte des erreurs de positionnement lors d’une radiothérapie conformationnelle tridimensionnelle pour un cancer du poumon non à petites cellules. Cancer Radiother 2009. [DOI: 10.1016/j.canrad.2009.08.116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
12
|
Berges O, Henni M, Gilliot O, Bolle S, Zefkili S, Benamor M, Giraud P. Tomothérapie des cancers ORL : évaluation scintigraphique prospective de la préservation des glandes salivaires. Cancer Radiother 2008. [DOI: 10.1016/j.canrad.2008.08.251] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
13
|
Chauveinc L, Flam T, Thiounn N, Gomme S, Rosenwald JC, Asselain B, Pontvert D, Henni M, Debré B, Cosset JM. Curiethérapie deprostate parimplantation permanente: résultats àcinqans dugroupe Curie–Cochin–Necker. Cancer Radiother 2007. [DOI: 10.1016/j.canrad.2007.09.101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
14
|
Cosset JM, Gomme S, Peiffert D, Guerif S, Labib A, Hannoun-Lévi JM, Martin P, Quétin P, Nguyen TD, Flam T, Thiounn N, Henni M, Rosenwald JC, Housset M, Pontvert D, Asselain B, Chauveinc L. Analyse clinique et dosimétrique de 469 patients traités en France en 2005 par implantation prostatique de grains d'iode 125 IsoSeed Bebig: rapport pour le Comité économique des produits de santé (CEPS). Cancer Radiother 2007; 11:206-13. [PMID: 17604675 DOI: 10.1016/j.canrad.2007.05.003] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2007] [Revised: 05/21/2007] [Accepted: 05/31/2007] [Indexed: 10/23/2022]
Abstract
A French decree of February 3rd 2005, allowed the Iodin 125 seeds from several companies to be reimbursed after a permanent implantation brachytherapy for a prostate cancer. Within this frame, the French "Comité économique des produits de santé" (CEPS; Economic committee for health products) made mandatory the annual writing and publication of a follow-up study with three main aims; make sure that the seeds were used for prostate cancer patients with criterias corresponding to the national recommendations, analyze the quality of the dosimetric data, and report all side effects, complications and possible accidents. We therefore report here a clinical and dosimetric analysis of 469 patient cases treated in France in nine centers in 2005 with the Iodin 125 IsoSeed Bebig. This analysis shows that: 1) The national recommendations for selecting patients for exclusive prostate brachytherapy have been taken into account in 97% of the cases; 2) The dosimetric quality criterias totally fulfilled the recommendations in a large majority of cases; the intra-operative D90 was found to be superior to 145 Gy in 98% of the patients, and the intra-operative V100 was superior to 95% in 96% of the cases; 3) The early toxicity (mainly urinary) was found to be at the lower range of what is reported in the literature, with in particular a retention rate of 2.4%.
Collapse
Affiliation(s)
- J-M Cosset
- Institut Curie, 26, rue d'Ulm, 75005 Paris, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Miranda O, Le Scodan R, Henni M, Durdux C, Landi B, Berger A, Dousset B, Brezault C, Meatchi T, Housset M. 2159. Int J Radiat Oncol Biol Phys 2006. [DOI: 10.1016/j.ijrobp.2006.07.564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
16
|
Le Scodan R, Miranda O, Henni M, Durdux C, Landi B, Berger A, Dousset B, Brezault C, Coté JF, Housset M. Chimioradiothérapie néoadjuvante par 5-fluoro-uracile et oxaliplatine pour les cancers du rectum localement évolués: étude de la toxicité et de la réponse histologique. Cancer Radiother 2006. [DOI: 10.1016/j.canrad.2006.09.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|